Cargando…
Biological intratumoral therapy for the high-grade glioma part I: intratumoral delivery and immunotoxins
Management of high-grade gliomas remains a complex challenge. Standard of care consists of microsurgical resection, chemotherapy and radiation, but despite these aggressive multimodality therapies the overall prognosis remains poor. A major focus of ongoing translational research studies is to devel...
Autores principales: | Loya, Joshua, Zhang, Charlie, Cox, Emily, Achrol, Achal S, Kesari, Santosh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Future Medicine Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6880302/ https://www.ncbi.nlm.nih.gov/pubmed/31747788 http://dx.doi.org/10.2217/cns-2019-0001 |
Ejemplares similares
-
Biological intratumoral therapy for the high-grade glioma part II: vector- and cell-based therapies and radioimmunotherapy
por: Loya, Joshua, et al.
Publicado: (2019) -
Intratumoral anti-HuD immunotoxin therapy for small cell lung cancer and neuroblastoma
por: Ehrlich, Debra, et al.
Publicado: (2014) -
Intratumoral Susceptibility Signals Reflect Biomarker Status in Gliomas
por: Kong, Ling-Wei, et al.
Publicado: (2019) -
Lipid–polymer hybrid nanoparticles as a next-generation drug delivery platform: state of the art, emerging technologies, and perspectives
por: Mukherjee, Anubhab, et al.
Publicado: (2019) -
Biological characteristics of intratumoral [F-18]-fluoromisonidazole distribution in a rodent model of glioma
por: HATANO, TOSHIYUKI, et al.
Publicado: (2013)